Global Benign Prostatic Hyperplasia (BPH) Drugs Industry Growth and Trends Forecast to 2031

Summary

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.

According to APO Research, The global Benign Prostatic Hyperplasia (BPH) Drugs market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Benign Prostatic Hyperplasia (BPH) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Benign Prostatic Hyperplasia (BPH) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Benign Prostatic Hyperplasia (BPH) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs include Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, Abbott, Allergan, TEVA and Mylan, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Benign Prostatic Hyperplasia (BPH) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Benign Prostatic Hyperplasia (BPH) Drugs.

The Benign Prostatic Hyperplasia (BPH) Drugs market size, estimations, and forecasts are provided in terms of sales volume (M Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Benign Prostatic Hyperplasia (BPH) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Benign Prostatic Hyperplasia (BPH) Drugs Segment by Company

Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck

Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type

Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others

Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application

Hospitals
Drugstores
Others

Benign Prostatic Hyperplasia (BPH) Drugs Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Benign Prostatic Hyperplasia (BPH) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Benign Prostatic Hyperplasia (BPH) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Benign Prostatic Hyperplasia (BPH) Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Benign Prostatic Hyperplasia (BPH) Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Benign Prostatic Hyperplasia (BPH) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview

1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Estimates and Forecasts (2020-2031)
1.3 Benign Prostatic Hyperplasia (BPH) Drugs Market by Type
1.3.1 Alpha-Blocker
1.3.2 Phosphodiesterase Type-5 Inhibitors
1.3.3 Others
1.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
1.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Overview by Type (2020-2031)
1.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Size Review by Type (2020-2025)
1.4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2020-2025)
1.5.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2020-2025)
1.5.4 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics

2.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends
2.2 Benign Prostatic Hyperplasia (BPH) Drugs Industry Drivers
2.3 Benign Prostatic Hyperplasia (BPH) Drugs Industry Opportunities and Challenges
2.4 Benign Prostatic Hyperplasia (BPH) Drugs Industry Restraints
3 Market Competitive Landscape by Company

3.1 Global Top Players by Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2020-2025)
3.2 Global Top Players by Benign Prostatic Hyperplasia (BPH) Drugs Sales (2020-2025)
3.3 Global Top Players by Benign Prostatic Hyperplasia (BPH) Drugs Price (2020-2025)
3.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global Benign Prostatic Hyperplasia (BPH) Drugs Major Company Production Sites & Headquarters
3.6 Global Benign Prostatic Hyperplasia (BPH) Drugs Company, Product Type & Application
3.7 Global Benign Prostatic Hyperplasia (BPH) Drugs Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market CR5 and HHI
3.8.2 Global Top 5 and 10 Benign Prostatic Hyperplasia (BPH) Drugs Players Market Share by Revenue in 2024
3.8.3 2023 Benign Prostatic Hyperplasia (BPH) Drugs Tier 1, Tier 2, and Tier 3
4 Benign Prostatic Hyperplasia (BPH) Drugs Regional Status and Outlook

4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Size by Region
4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Region (2020-2025)
4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales in Value by Region (2020-2025)
4.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Market Size by Region
4.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Region (2026-2031)
4.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales in Value by Region (2026-2031)
4.3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Benign Prostatic Hyperplasia (BPH) Drugs by Application

5.1 Benign Prostatic Hyperplasia (BPH) Drugs Market by Application
5.1.1 Hospitals
5.1.2 Drugstores
5.1.3 Others
5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
5.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Overview by Application (2020-2031)
5.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Size Review by Application (2020-2025)
5.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2020-2025)
5.3.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2020-2025)
5.3.4 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2020-2025)
6 Company Profiles

6.1 Eli Lilly
6.1.1 Eli Lilly Comapny Information
6.1.2 Eli Lilly Business Overview
6.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.1.5 Eli Lilly Recent Developments
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Comapny Information
6.2.2 GlaxoSmithKline Business Overview
6.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.2.5 GlaxoSmithKline Recent Developments
6.3 Astellas Pharma
6.3.1 Astellas Pharma Comapny Information
6.3.2 Astellas Pharma Business Overview
6.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.3.5 Astellas Pharma Recent Developments
6.4 Sanofi
6.4.1 Sanofi Comapny Information
6.4.2 Sanofi Business Overview
6.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.4.5 Sanofi Recent Developments
6.5 Pfizer
6.5.1 Pfizer Comapny Information
6.5.2 Pfizer Business Overview
6.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.5.5 Pfizer Recent Developments
6.6 Abbott
6.6.1 Abbott Comapny Information
6.6.2 Abbott Business Overview
6.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.6.5 Abbott Recent Developments
6.7 Allergan
6.7.1 Allergan Comapny Information
6.7.2 Allergan Business Overview
6.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.7.5 Allergan Recent Developments
6.8 TEVA
6.8.1 TEVA Comapny Information
6.8.2 TEVA Business Overview
6.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.8.5 TEVA Recent Developments
6.9 Mylan
6.9.1 Mylan Comapny Information
6.9.2 Mylan Business Overview
6.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.9.5 Mylan Recent Developments
6.10 Novartis
6.10.1 Novartis Comapny Information
6.10.2 Novartis Business Overview
6.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.10.5 Novartis Recent Developments
6.11 Merck
6.11.1 Merck Comapny Information
6.11.2 Merck Business Overview
6.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.11.5 Merck Recent Developments
7 North America by Country

7.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
7.1.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025)
7.1.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2026-2031)
7.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
7.2.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country (2020-2025)
7.2.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Country (2026-2031)
8 Europe by Country

8.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
8.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025)
8.1.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2026-2031)
8.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
8.2.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country (2020-2025)
8.2.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country

9.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
9.1.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025)
9.1.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
9.2.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country (2020-2025)
9.2.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Country (2026-2031)
10 South America by Country

10.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
10.1.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025)
10.1.3 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2026-2031)
10.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
10.2.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country (2020-2025)
10.2.3 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country

11.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
11.1.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025)
11.1.3 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
11.2.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country (2020-2025)
11.2.3 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis

12.1 Benign Prostatic Hyperplasia (BPH) Drugs Value Chain Analysis
12.1.1 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Benign Prostatic Hyperplasia (BPH) Drugs Production Mode & Process
12.2 Benign Prostatic Hyperplasia (BPH) Drugs Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
12.2.3 Benign Prostatic Hyperplasia (BPH) Drugs Customers
13 Concluding Insights
14 Appendix

14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings